363 related articles for article (PubMed ID: 17283142)
21. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues.
Kim IY; Ahn HJ; Zelner DJ; Shaw JW; Lang S; Kato M; Oefelein MG; Miyazono K; Nemeth JA; Kozlowski JM; Lee C
Clin Cancer Res; 1996 Aug; 2(8):1255-61. PubMed ID: 9816295
[TBL] [Abstract][Full Text] [Related]
22. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation.
Muñoz NM; Upton M; Rojas A; Washington MK; Lin L; Chytil A; Sozmen EG; Madison BB; Pozzi A; Moon RT; Moses HL; Grady WM
Cancer Res; 2006 Oct; 66(20):9837-44. PubMed ID: 17047044
[TBL] [Abstract][Full Text] [Related]
23. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.
Tobin SW; Douville K; Benbow U; Brinckerhoff CE; Memoli VA; Arrick BA
Oncogene; 2002 Jan; 21(1):108-18. PubMed ID: 11791181
[TBL] [Abstract][Full Text] [Related]
24. Development and characterization of DP-153, a nontumorigenic prostatic cell line that undergoes malignant transformation by expression of dominant-negative transforming growth factor beta receptor type II.
Song K; Cornelius SC; Danielpour D
Cancer Res; 2003 Aug; 63(15):4358-67. PubMed ID: 12907605
[TBL] [Abstract][Full Text] [Related]
25. Loss of expression of TGF-beta1, TbetaRI, and TbetaRII correlates with differentiation in human oral squamous cell carcinomas.
Mincione G; Di Marcantonio MC; Artese L; Vianale G; Piccirelli A; Piccirilli M; Perrotti V; Rubini C; Piattelli A; Muraro R
Int J Oncol; 2008 Feb; 32(2):323-31. PubMed ID: 18202754
[TBL] [Abstract][Full Text] [Related]
26. Evolution of the androgen receptor pathway during progression of prostate cancer.
Hendriksen PJ; Dits NF; Kokame K; Veldhoven A; van Weerden WM; Bangma CH; Trapman J; Jenster G
Cancer Res; 2006 May; 66(10):5012-20. PubMed ID: 16707422
[TBL] [Abstract][Full Text] [Related]
27. Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor.
Wesolowska A; Kwiatkowska A; Slomnicki L; Dembinski M; Master A; Sliwa M; Franciszkiewicz K; Chouaib S; Kaminska B
Oncogene; 2008 Feb; 27(7):918-30. PubMed ID: 17684491
[TBL] [Abstract][Full Text] [Related]
28. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.
Lu S; Lee J; Revelo M; Wang X; Lu S; Dong Z
Clin Cancer Res; 2007 Oct; 13(19):5692-702. PubMed ID: 17908958
[TBL] [Abstract][Full Text] [Related]
29. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
[TBL] [Abstract][Full Text] [Related]
30. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread.
Narla G; DiFeo A; Yao S; Banno A; Hod E; Reeves HL; Qiao RF; Camacho-Vanegas O; Levine A; Kirschenbaum A; Chan AM; Friedman SL; Martignetti JA
Cancer Res; 2005 Jul; 65(13):5761-8. PubMed ID: 15994951
[TBL] [Abstract][Full Text] [Related]
31. Aberrant expression and mutations of TGF-beta receptor type II gene in endometrial cancer.
Sakaguchi J; Kyo S; Kanaya T; Maida Y; Hashimoto M; Nakamura M; Yamada K; Inoue M
Gynecol Oncol; 2005 Sep; 98(3):427-33. PubMed ID: 15993480
[TBL] [Abstract][Full Text] [Related]
32. Fibroblast and prostate tumor cell cross-talk: fibroblast differentiation, TGF-β, and extracellular matrix down-regulation.
Coulson-Thomas VJ; Gesteira TF; Coulson-Thomas YM; Vicente CM; Tersariol IL; Nader HB; Toma L
Exp Cell Res; 2010 Nov; 316(19):3207-26. PubMed ID: 20727350
[TBL] [Abstract][Full Text] [Related]
33. Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer.
Biswas S; Chytil A; Washington K; Romero-Gallo J; Gorska AE; Wirth PS; Gautam S; Moses HL; Grady WM
Cancer Res; 2004 Jul; 64(14):4687-92. PubMed ID: 15256431
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
35. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
[TBL] [Abstract][Full Text] [Related]
36. Cystatin C antagonizes transforming growth factor beta signaling in normal and cancer cells.
Sokol JP; Schiemann WP
Mol Cancer Res; 2004 Mar; 2(3):183-95. PubMed ID: 15037657
[TBL] [Abstract][Full Text] [Related]
37. Role of transforming growth factor-beta1 in prostate cancer.
Wikström P; Damber J; Bergh A
Microsc Res Tech; 2001 Feb; 52(4):411-9. PubMed ID: 11170300
[TBL] [Abstract][Full Text] [Related]
38. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity.
Hua D; Liu MY; Cheng ZD; Qin XJ; Zhang HM; Chen Y; Qin GJ; Liang G; Li JN; Han XF; Liu DX
Mol Immunol; 2009 Sep; 46(15):2876-84. PubMed ID: 19643479
[TBL] [Abstract][Full Text] [Related]
39. Androgen receptor regulates CD168 expression and signaling in prostate cancer.
Lin SL; Chang D; Chiang A; Ying SY
Carcinogenesis; 2008 Feb; 29(2):282-90. PubMed ID: 18174258
[TBL] [Abstract][Full Text] [Related]
40. Bcl-2 antagonizes the combined apoptotic effect of transforming growth factor-beta and dihydrotestosterone in prostate cancer cells.
Bruckheimer EM; Kyprianou N
Prostate; 2002 Oct; 53(2):133-42. PubMed ID: 12242728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
